Archives of Academic Emergency Medicine

Amimo F, Lambert B, Magit A, Hashizume M. A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa. Globalization and health. 2021;17(1):42.

Gubernot D, Jazwa A, Niu M, Baumblatt J, Gee J, Moro P, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine. 2021;39(28):3666-77.

Dadras O, Alinaghi SAS, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. European journal of medical research. 2021;26(1):67.

Joshi RK, Muralidharan CG, Gulati DS, Mopagar V, Dev JK, Kuthe S, et al. Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. Medical journal, Armed Forces India. 2021;77(Suppl 2):S505-s7.

Bukhari MH, Syed M, Zain S. The Differences between Traditional Vaccines and RNA Vaccines: Safety, Efficacy, Reliability and Future of COVID-19 Vaccines. Annals of King Edward Medical University Lahore Pakistan. 2021;27(2):172-82.

Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021;10(8):752.

Organization WH. 10 Vaccines Approved for Use by WHO: WORLD HEALTH ORGANIZATION (WHO); 2021 [updated 22 December 2021; cited 2021 23 December ]. Available from: https://covid19.trackvaccines.org/agency/who/.

Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Frontiers in immunology. 2021;12:701501.

Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of COVID-19 vaccines. Journal of medical virology. 2021;93(12):6588-94.

Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021;9(6).

Coggins SAA, Laing ED, Olsen CH, Goguet E, Moser M, Jackson-Thompson BM, et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. medRxiv : the preprint server for health sciences. 2021.

Botwin GJ, Li D, Figueiredo J, Cheng S, Braun J, McGovern DPB, et al. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease. The American journal of gastroenterology. 2021.

Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2021;50(4):424-7.

MacIntyre CR, Veness B, Berger D, Hamad N, Bari N. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia. Vaccine. 2021;39(34):4784-7.

Manzo C, Natale M, Castagna A. Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: A case report and review of literature. Aging medicine (Milton (NSW)). 2021;4(3):234-8.

Park C, Sakong J, Jo S, Kim M, Baek K. Adverse Effects on Work and Daily Life Interference among Healthcare Workers after the First and Second ChAdOx1 and BNT162b2 COVID-19 Vaccine Doses. Vaccines. 2021;9(8).

Karayeva E, Kim HW, Bandy U, Clyne A, Marak TP. Monitoring Vaccine Adverse Event Reporting System (VAERS) Reports Related to COVID-19 Vaccination Efforts in Rhode Island. Rhode Island medical journal (2013). 2021;104(7):64-6.

Andrzejczak-Grządko S, Czudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. European review for medical and pharmacological sciences. 2021;25(12):4418-21.

Bogdanov G, Bogdanov I, Kazandjieva J, Tsankov N. Cutaneous adverse effects of the available COVID-19 vaccines. Clinics in dermatology. 2021;39(3):523-31.

Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;106:376-81.

Jeet Kaur R, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, et al. Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. International journal of general medicine. 2021;14:3909-27.

Eyal N, Gerhard T, Strom BL. Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests. Vaccine. 2021;39(26):3455-8.

SeyedAlinaghi S, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. European journal of medical research. 2021;26(1):51.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;384(5):403-16.

Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. The New England journal of medicine. 2021;385(12):1078-90.

Bardenheier BH, Gravenstein S, Blackman C, Gutman R, Sarkar IN, Feifer RA, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine. 2021;39(29):3844-51.

Kadali RAK, Janagama R, Peruru S, Gajula V, Madathala RR, Chennaiahgari N, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. Journal of medical virology. 2021;93(7):4420-9.

Polewska K, Tylicki P, Biedunkiewicz B, Rucińska A, Szydłowska A, Kubanek A, et al. Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project. Medicina (Kaunas, Lithuania). 2021;57(7).

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine. 2020;383(27):2603-15.

Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. The New England journal of medicine. 2021;384(24):2273-82.

Blakeway H, Prasad S, Kalafat E, Heath PT, Ladhani SN, Le Doare K, et al. COVID-19 vaccination during pregnancy: coverage and safety. American journal of obstetrics and gynecology. 2022;226(2):236.e1-.e14.

Heidary F, Gharebaghi R, Lateef M, Mohammed MZA, Alshmailawi SFH, Alkhafaji K, et al. Antiviral vector effects of ivermectin on COVID-19: An update. J Cell Mol Anesth. 2021;6(1):101-3.

Iguchi T, Umeda H, Kojima M, Kanno Y, Tanaka Y, Kinoshita N, et al. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug safety. 2021;44(11):1209-14.

Parvej MI, Sultana S, Tabassum M, Mannan SE, Ahmed F. Determinants of COVID-19 vaccine acceptance and encountered side-effects among the vaccinated in Bangladesh. Asian Pac J Trop Med. 2021;14(8):341-9.

Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021;10(8).

Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101-2.

Lotan I, Romanow G, Levy M. Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. Multiple sclerosis and related disorders. 2021;55:103189.

Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. European journal of neurology. 2021.

Matarneh AS, Al-Battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clinical case reports. 2021;9(9):e04756.

García-Grimshaw M, Ceballos-Liceaga SE, Hernández-Vanegas LE, Núñez I, Hernández-Valdivia N, Carrillo-García DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study. Clinical immunology (Orlando, Fla). 2021;229:108786.

Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. European journal of neurology. 2021;28(11):3742-8.

Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, et al. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. Transplantation and cellular therapy. 2021;27(9):788-94.

Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. The Lancet Oncology. 2021;22(6):765-78.

So ACP, McGrath H, Ting J, Srikandarajah K, Germanou S, Moss C, et al. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers. 2021;13(14).

Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021;36(4):1-13.

Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines. 2021;9(10).

Istampoulouoglou I, Dimitriou G, Späni S, Christ A, Zimmermanns B, Koechlin S, et al. Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract. 2021;2021(3):e202118.

Aye YN, Mai AS, Zhang A, Lim OZH, Lin N, Ng CH, et al. Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM : monthly journal of the Association of Physicians. 2021.

Falsaperla R, Leone G, Familiari M, Ruggieri M. COVID-19 vaccination in pregnant and lactating women: a systematic review. Expert Rev Vaccines. 2021;20(12):1619-28.

Fu W, Sivajohan B, McClymont E, Albert A, Elwood C, Ogilvie G, et al. Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2022;156(3):406-17.

Alhumaid S, Al Mutair A, Al Alawi Z, Rabaan AA, Tirupathi R, Alomari MA, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109.

Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract. 2021;9(10):3546-67.

Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study. The BMJ. 2021;373.

Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3-40.

Kozlovskaya LI, Piniaeva AN, Ignatyev GM, Gordeychuk IV, Volok VP, Rogova YV, et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerging microbes & infections. 2021;10(1):1790-806.

Abu-Halaweh S, Alqassieh R, Suleiman A, Al-Sabbagh MQ, AbuHalaweh M, AlKhader D, et al. Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. Vaccines. 2021;9(9):950.

Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9(6):577.

Al Ghafri TS, Al Balushi L, Al Balushi Z, Al Hinai F, Al Hasani S, Anwar H, et al. Reporting at Least One Adverse Effect Post-COVID-19 Vaccination From Primary Health Care in Muscat. Cureus. 2021;13(8):e17055.

Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. The New England journal of medicine. 2020;383(25):2427-38.

Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, et al. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. British journal of haematology. 2021;195(4):523-31.

Caminati M, Guarnieri G, Batani V, Scarpieri E, Finocchiaro A, Chieco-Bianchi F, et al. COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control. Vaccines. 2021;9(8):853.

Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021;27(12):1851-5.

Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature medicine. 2021;27(6):1062-70.

Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ (Clinical research ed). 2021;373:n1435.

Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A, et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. Journal of the National Cancer Institute. 2022;114(2):203-9.

Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet (London, England). 2021;398(10303):856-69.

Maeda K, Amano M, Uemura Y, Tsuchiya K, Matsushima T, Noda K, et al. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. medRxiv : the preprint server for health sciences. 2021.

Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and drug resistance. 2021;14:3459-76.

Massoud F, Ahmad SF, Hassan AM, Alexander KJ, Al-Hashel J, Arabi M. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study. Seizure. 2021;92:2-9.

Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, et al. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel, Switzerland). 2021;11(3):249.

McMurry R, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (New York, NY). 2021;2(8):965-78.e5.

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious diseases. 2021;21(7):939-49.

Modenese A, Paduano S, Bargellini A, Bellucci R, Marchetti S, Bruno F, et al. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart. Vaccines. 2021;9(6):652.

Hall VG, Ferreira VH, Ierullo M, Ku T, Marinelli T, Majchrzak-Kita B, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2021;21(12):3980-9.

Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines. 2021;9(6):556.

Kim T, Park SY, Yu S, Park JW, Lee E, Jeon MH, et al. Impacts of Side Effects to BNT162b2 and the First Dose of ChAdOx1 Anti-SARS-CoV-2 Vaccination on Work Productivity, the Need for Medical Attention, and Vaccine Acceptance: A Multicenter Survey on Healthcare Workers in Referral Teaching Hospitals in the Republic of Korea. Vaccines. 2021;9(6):648.

Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. Journal of clinical medicine. 2021;10(7).

Riad A, Hocková B, Kantorová L, Slávik R, Spurná L, Stebel A, et al. Side effects of mrna-based covid-19 vaccine: Nationwide phase iv study among healthcare workers in slovakia. Pharmaceuticals. 2021;14(9).

Rechavi Y, Shashar M, Lellouche J, Yana M, Yakubovich D, Sharon N. Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response. Vaccines. 2021;9(9):977.

Quiroga B, Sánchez-Álvarez E, Goicoechea M, de Sequera P. COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects. Journal of healthcare quality research. 2021;36(6):363-9.

Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. Journal of hematology & oncology. 2021;14(1):81.

Panda DS, Giri RK, Nagarajappa AK, Basha S. Covid-19 vaccine, acceptance, and concern of safety from public perspective in the state of Odisha, India. Human vaccines & immunotherapeutics. 2021;17(10):3333-7.

Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, et al. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021;105(10):2170-4.

Oh HK, Kim EK, Hwang I, Kim TE, Lee YK, Lee E, et al. COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021. Osong public health and research perspectives. 2021;12(4):264-8.

Morales-Núñez JJ, Muñoz-Valle JF, Meza-López C, Wang LF, Machado Sulbarán AC, Torres-Hernández PC, et al. Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. Vaccines. 2021;9(7):742.

Tissot N, Brunel AS, Bozon F, Rosolen B, Chirouze C, Bouiller K. Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine. Vaccine. 2021;39(36):5087-90.

Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, et al. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Frontiers in immunology. 2021;12:704773.

Xiong X, Yuan J, Li M, Jiang B, Lu ZK. Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management. Frontiers in medicine. 2021;8:700014.

Wi YM, Kim SH, Peck KR. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers. Vaccines. 2021;9(8):931.

Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of internal medicine. 2021;174(9):1330-2.

Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England journal of medicine. 2020;383(25):2439-50.

Skroza N, Bernardini N, Tolino E, Proietti I, Mambrin A, Marchesiello A, et al. Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. Journal of clinical medicine. 2021;10(15):3355.

Rotondo C, Cantatore FP, Fornaro M, Colia R, Busto G, Rella V, et al. Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study. Vaccines. 2021;9(7):730.

Chen YW, Tucker MD, Beckermann KE, Iams WT, Rini BI, Johnson DB. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. European journal of cancer (Oxford, England : 1990). 2021;155:291-3.

Chevallier P, Coste-Burel M, Le Bourgeois A, Peterlin P, Garnier A, Béné MC, et al. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients. EJHaem. 2021;2(3):520-4.

Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39(20):2791-9.

Efrati S, Catalogna M, Abu Hamad R, Hadanny A, Bar-Chaim A, Benveniste-Levkovitz P, et al. Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations. Scientific reports. 2021;11(1):16543.

El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. International journal of general medicine. 2021;14:1389-401.

Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. The New England journal of medicine. 2021;385(3):239-50.

Golan Y, Prahl M, Cassidy AG, Gay C, Wu AHB, Jigmeddagva U, et al. COVID-19 mRNA Vaccination in Lactation: Assessment of adverse effects and transfer of anti-SARS-CoV2 antibodies from mother to child. medRxiv : the preprint server for health sciences. 2021.